A single-centre feasibility study to evaluate the ability of Phoxilium to prevent hypophoshatemia compared to Hemosol B0 or Prismocol B22 during continuous renal replacement therapy in the intensive care unit

Phase 2

Recruiting

• Conditions: Acute kidney injury; Renal and Urogenital - Other renal and urogenital disorders

• Registration Number: ACTRN12623001152617
• Lead Sponsor: Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-11-08
• Last Update Posted: 21 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

Patients will be included from the study if ALL the following criteria are present:
Have severe acute kidney injury.
Continuous renal replacement therapy is to commence.
Will receive regional citrate anticoagulation as a component of CRRT.
Expected to receive CRRT for equal to or greater than 48 hours.
The treating clinician believe that using Phoxilium® or Hemosol B0 are equally indicated and appropriate.

Exclusion Criteria

Patients will be EXCLUDED from the study if ONE of the following criteria presents:
Age is less than 18 years of age.
Pregnancy
Not For Resuscitation (NFR) order in place during the index intensive care unit admission
Death is deemed imminent or inevitable during this admission, and either the attending physician, patient or substitute decision-maker is not committed to active treatment.
Patients with known HIV infection
Any other illness that, in the investigator’s judgement, will substantially increase the risk associated with subject’s participation in this study.
Patient needs to receive systemic anticoagulation for other indications.

Study & Design

• Study Type: Interventional
• Study Design: Not specified